Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

NCT06640972 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Triglycerides
Weight Gain Trajectory
Cholesterol, Elevated

Interventions

DRUG: RDX-002
DRUG: Placebo

Sponsor

Response Pharmaceuticals